Investment Thesis

We target oncology, neurosciences, rare disease, and antimicrobial resistance. In addition to targeting these disease states with patients in need, we look for biotech and medtech companies dramatically changing how medicine is practiced. We have a particular interest in supporting companies with disruptive technologies in cell and gene therapy, gene editing, and mRNA/RNAi, all technologies.

New From Kineticos

Press Release
March 28, 2023

EnteroBiotix Initiates Phase 2 Study

IMPuLSE Intestinal Microbiota Product in Liver Cirrhosis and Encephalopathy GLASGOW, United Kingdom | March 28, 2023 – EnteroBiotix Limited (“EBX”),…